Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
-
Published:2022-11
Issue:
Volume:175
Page:31-40
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Lepage Côme, Phelip Jean-Marc, Lievre AstridORCID, Le-Malicot Karine, Dahan Laetitia, Tougeron DavidORCID, Toumpanakis Christos, Di-Fiore Frédéric, Lombard-Bohas Catherine, Borbath IvanORCID, Coriat Romain, Lecomte ThierryORCID, Guimbaud Rosine, Petorin Caroline, Legoux Jean-Louis, Michel Pierre, Scoazec Jean-Yves, Smith Denis, Walter ThomasORCID
Subject
Cancer Research,Oncology
Reference25 articles.
1. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol,2017 2. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study;Lepage;Gastroenterology,2007 3. Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours;Lepage;Eur J Endocrinol,2013 4. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression;Panzuto;J Clin Oncol,2011 5. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR);de Mestier;Dig Liver Dis,2020
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|